Storia in 2 fonti

Evommune's lead drug fails in chronic hives, stock sinks

Evommune shares fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo12 g fa

Evommune shares fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year.

Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.